JP2016514672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514672A5 JP2016514672A5 JP2016501829A JP2016501829A JP2016514672A5 JP 2016514672 A5 JP2016514672 A5 JP 2016514672A5 JP 2016501829 A JP2016501829 A JP 2016501829A JP 2016501829 A JP2016501829 A JP 2016501829A JP 2016514672 A5 JP2016514672 A5 JP 2016514672A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- antigen
- nucleic acid
- subject
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 230000028993 immune response Effects 0.000 claims 7
- 241000701806 Human papillomavirus Species 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 241000223960 Plasmodium falciparum Species 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 claims 1
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000008447 perception Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361788942P | 2013-03-15 | 2013-03-15 | |
| US61/788,942 | 2013-03-15 | ||
| PCT/US2014/025348 WO2014151279A1 (en) | 2013-03-15 | 2014-03-13 | Vaccines having an antigen and interleukin-23 as an adjuvant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016514672A JP2016514672A (ja) | 2016-05-23 |
| JP2016514672A5 true JP2016514672A5 (enExample) | 2017-03-30 |
Family
ID=51580923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501829A Pending JP2016514672A (ja) | 2013-03-15 | 2014-03-13 | 抗原およびアジュバントとしてのインターロイキン−２３を有するワクチン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9669091B2 (enExample) |
| EP (1) | EP2968500A4 (enExample) |
| JP (1) | JP2016514672A (enExample) |
| KR (1) | KR20150128900A (enExample) |
| CN (1) | CN105209063A (enExample) |
| AU (1) | AU2014235120B2 (enExample) |
| CA (1) | CA2898237A1 (enExample) |
| WO (1) | WO2014151279A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105744953B (zh) * | 2013-10-07 | 2020-01-17 | 宾夕法尼亚大学理事会 | 具有作为佐剂的白介素-33的疫苗 |
| WO2019151759A1 (ko) | 2018-02-02 | 2019-08-08 | 주식회사 에스엘백시젠 | 신규 백신 면역보조제 |
| CN108383913A (zh) * | 2018-02-12 | 2018-08-10 | 四川大学 | 重组猪il-23增强pcv2疫苗免疫佐剂的制备及应用 |
| KR102285977B1 (ko) * | 2019-03-15 | 2021-08-05 | 대한민국 | 오일 에멀젼과 병용 투여 가능한 면역증강용 보조물질 및 이를 포함하는 구제역 백신 조성물 |
| JP2023504659A (ja) | 2019-12-03 | 2023-02-06 | ニューボーゲン，インコーポレイティド | 腫瘍細胞ワクチン |
| TW202146435A (zh) * | 2020-03-04 | 2021-12-16 | 美商昂科賽醫藥公司 | 含有病原性抗原及免疫刺激物之組合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL113817A (en) * | 1994-06-30 | 2001-03-19 | Merck & Co Inc | Polynucleotide vaccne for papillomavirus |
| IL164281A0 (en) | 2002-04-01 | 2005-12-18 | Euro Celtique Sa | Epitope constructs comprising antigen presenting cell targeting mechanisms |
| GB0329146D0 (en) | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2005108425A1 (en) * | 2004-05-10 | 2005-11-17 | Cytos Biotechnology Ag | Il-23 p19 antigen array and uses thereof |
| US8765146B2 (en) * | 2005-08-31 | 2014-07-01 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| KR101492524B1 (ko) * | 2006-02-02 | 2015-02-12 | 글로브이뮨 | 면역 반응 유도를 위한 효모-기반 백신 |
| US20080260765A1 (en) | 2007-03-15 | 2008-10-23 | Johns Hopkins University | HPV DNA Vaccines and Methods of Use Thereof |
| NZ604415A (en) * | 2010-07-20 | 2014-10-31 | Cephalon Australia Pty Ltd | Anti-il-23 heterodimer specific antibodies |
| JP5981436B2 (ja) * | 2010-10-01 | 2016-08-31 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用 |
| US8802076B2 (en) | 2010-10-04 | 2014-08-12 | Duke University | Compositions and methods for modulating an immune response |
| EP3336096A1 (en) | 2011-12-12 | 2018-06-20 | The Trustees Of The University Of Pennsylvania | Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same |
| CN103555734B (zh) * | 2012-09-17 | 2015-07-15 | 青岛康立泰药业有限公司 | 人白细胞介素-12的编码基因、真核宿主细胞和表达方法 |
-
2014
- 2014-03-13 EP EP14767446.9A patent/EP2968500A4/en not_active Withdrawn
- 2014-03-13 US US14/775,087 patent/US9669091B2/en active Active
- 2014-03-13 CA CA2898237A patent/CA2898237A1/en not_active Abandoned
- 2014-03-13 WO PCT/US2014/025348 patent/WO2014151279A1/en not_active Ceased
- 2014-03-13 CN CN201480013830.6A patent/CN105209063A/zh active Pending
- 2014-03-13 AU AU2014235120A patent/AU2014235120B2/en not_active Ceased
- 2014-03-13 KR KR1020157028132A patent/KR20150128900A/ko not_active Ceased
- 2014-03-13 JP JP2016501829A patent/JP2016514672A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520530A5 (enExample) | ||
| JP2016514672A5 (enExample) | ||
| JP2019526580A5 (enExample) | ||
| JP2016516723A5 (enExample) | ||
| FI4023249T3 (fi) | Nukleiinihapporokotteita | |
| JP2016539946A5 (enExample) | ||
| JP2016506416A5 (enExample) | ||
| MX2023006203A (es) | Vacunas novedosas contra el virus de zika. | |
| CN106659777A8 (zh) | 免疫原性组合产品 | |
| HK1254344A1 (zh) | 抗原匹配的流感疫苗 | |
| JP2015501840A5 (enExample) | ||
| Rezaei et al. | Recent advances on HIV DNA vaccines development: Stepwise improvements to clinical trials | |
| MX2020011804A (es) | Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas. | |
| MY180109A (en) | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza | |
| WO2015195218A8 (en) | Polyvalent influenza virus-like particles (vlps) and use as vaccines | |
| WO2008060385A3 (en) | Li-key enhanced vaccine potency | |
| Garg et al. | Development of novel carrier (s) mediated tuberculosis vaccine: more than a tour de force | |
| JP2010506926A5 (enExample) | ||
| FI3220937T3 (fi) | Pneumolysiinimutantteja ja menetelmiä niiden käyttämiseksi | |
| JP2014139185A5 (enExample) | ||
| JP2019505567A5 (enExample) | ||
| JP2018501258A5 (enExample) | ||
| AU2017261706A1 (en) | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | |
| WO2011038473A8 (pt) | Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos | |
| EA033242B1 (ru) | Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением |